Cited by Crossref (17)

  1. А. А. Shikaleva, M. L. Maksimov, E. A. Kanunikova. Modern approaches to drug treatment of obesity. Pharmacy and Pharmaceutical Technology 2023:30
    https://doi.org/10.33920/med-13-2305-03
  2. Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas, Mark Y. Chan. Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity 2024;32:840
    https://doi.org/10.1002/oby.24002
  3. Carolyn S. P. Lam, Kieran F. Docherty, Jennifer E. Ho, John J. V. McMurray, Peder L. Myhre, Torbjørn Omland. Recent successes in heart failure treatment. Nat Med 2023;29:2424
    https://doi.org/10.1038/s41591-023-02567-2
  4. Sten Madsbad. Challenges in the treatment of young people with type 2 diabetes. The Lancet Diabetes & Endocrinology 2023;11:141
    https://doi.org/10.1016/S2213-8587(23)00030-X
  5. Dughyun Choi. Recent Progression of Incretin-Based Obesity Treatment. Korean J Med 2024;99:78
    https://doi.org/10.3904/kjm.2024.99.2.78
  6. A. I. Islamova, A. R. Sabirova, E. R. Batyrshina, G. N. Muzafarova, L. H. Khabibullina , A. E. Kiraeva, A. V. Pyatyshina, E. F. Arslanova, A. A. Vinnikova, A. A. Pisarev, A F. Nabiullina, A. I. Gimazieva , K. O. Kuznetsov. New class of drugs for the treatment of diabetes mellitus. jour 2024;102:499
    https://doi.org/10.30629/0023-2149-2024-102-7-499-509
  7. Sidar Copur, Cem Tanriover, Furkan Yavuz, Katherine R. Tuttle, Mehmet Kanbay. Tirzepatide and potential use for metabolically healthy obesity. European Journal of Internal Medicine 2023;113:1
    https://doi.org/10.1016/j.ejim.2023.05.012
  8. Gaber El-Saber Batiha, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nada A. Ashour, Walaa A. Negm. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Inflammopharmacol 2023;31:1683
    https://doi.org/10.1007/s10787-023-01239-4
  9. Bo Kyung Koo. Non-pharmacologic treatment for obesity. J Korean Med Assoc 2022;65:400
    https://doi.org/10.5124/jkma.2022.65.7.400
  10. Bryan Tan, Xin-Hui Pan, Han Shi Jocelyn Chew, Rachel Sze Jen Goh, Chaoxing Lin, Vickram Vijay Anand, Ethan Cheng Zhe Lee, Kai En Chan, Gwyneth Kong, Christen En Ya Ong, Hui Charlotte Chung, Dan Yock Young, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mark Dhinesh Muthiah, Mazen Noureddin, Cheng Han Ng, Nicholas W. S. Chew, Yip Han Chin. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes 2023;47:677
    https://doi.org/10.1038/s41366-023-01321-5
  11. Eun-Jung Rhee. Current status of obesity treatment in Korea: based on the 2020 Korean Society for the Study of Obesity guidelines for obesity management. J Korean Med Assoc 2022;65:388
    https://doi.org/10.5124/jkma.2022.65.7.388
  12. Maja Cigrovski Berkovic, Ines Bilic-Curcic, Anna Mrzljak, Silvija Canecki Varzic, Vjekoslav Cigrovski. Prehabilitation of overweight and obese patients with dysglycemia awaiting bariatric surgery: Predicting the success of obesity treatment. World J Diabetes 2022;13:1096
    https://doi.org/10.4239/wjd.v13.i12.1096
  13. Wenting Cai, Ruobin Zhang, Yao Yao, Qiuhui Wu, Jinping Zhang. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front. Public Health 2024;12
    https://doi.org/10.3389/fpubh.2024.1277113
  14. Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, Monika Różycka-Kosmalska, Tadeusz Pietras. Pharmacological Support for the Treatment of Obesity—Present and Future. Healthcare 2023;11:433
    https://doi.org/10.3390/healthcare11030433
  15. Mark A. Moyad. Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.). Curr Urol Rep 2023;24:515
    https://doi.org/10.1007/s11934-023-01180-7
  16. Rahaf Wardeh, Tabarak Haamid Elbo Iswadi, Hind Alsharayri, Fauzia Rashid, Nada Alhashemi, Alaaeldin Bashier. Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence. Journal of Diabetes and Endocrine Practice 2024;07:15
    https://doi.org/10.1055/s-0043-1775966
  17. Han Na Jung, Chang Hee Jung. Pharmacologic treatment of obesity. J Korean Med Assoc 2022;65:408
    https://doi.org/10.5124/jkma.2022.65.7.408